Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial (CAVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03661762|
Recruitment Status : Completed
First Posted : September 7, 2018
Results First Posted : December 10, 2020
Last Update Posted : December 10, 2020
|Condition or disease||Intervention/treatment|
|Optokinetic Nystagmus||Device: CAVA|
Dizziness is a common condition that is responsible for a significant degree of material morbidity and burden on the National Health Service. There are multiple causes of dizziness, and these originate from pathologies affecting a large variety of different organ systems. Dizziness is usually episodic and short-lived, so when a patient presents to their health care provider, examination is often normal. As such, diagnosis is challenging and patients often experience significant delay in receiving a diagnosis. The investigators have developed a prototype device for monitoring dizziness and have tested it in a small group of volunteers. The results showed that their device is capable of accurately, precisely and reliably identifying periods of dizziness over a short period of time. Independent market research has confirmed that their device could meet the required clinical need, would be desired by clinicians, and that there is no equivalent solution currently available. The investigators have received an award from the Medical Research Council to trial their device in a large cohort of healthy volunteers. Once completed, they will be positioned well to test their device in a cohort of patients with a defined dizziness syndrome, before further testing their device in a more diverse patient population. Once validated, developed and brought to market, the device would provide early diagnosis and accurate treatment for a significant proportion of the patient population. This would save the National Health Service money by reducing multiple visits to General Practitioner clinics, reducing referrals to multiple specialist clinics, and reducing treatment required from falls and other conditions associated with dizziness.
The overall aim of this trial is to test a fully evolved device for the continuous recording of eye movements over a prolonged period of time. For the purpose of this study, the monitoring period is 23 hours a day, for 30 days. The device is composed of two components: a bespoke single-use sensor array that adheres to the participant's face, and a small reusable module that contains a battery, microcomputer, data storage facility, battery and connection port.
The investigators intend to confirm that the device will be able to capture any occurrence, of a minimum period of thirty seconds, of artificially induced nystagmus, within a 24-hour period of time. Each participant will be provided with the device and enough single-use electrode arrays to allow the array to be changed every 24 hours, for thirty days. Participants will be allowed to remove the sensor array for up to 60 minutes each day to allow them to wash and/or shower. On eight of the thirty days for which they wear the array, each participant will be required to induce physiological nystagmus by viewing optokinetic video footage. The footage will be viewed on a portable screen (of a deactivated mobile phone) inside a Virtual Reality headset. These will be issued to the participants at the beginning of the trial. Participants will undertake the procedure whilst stationary for the first four days, and whilst walking gently on the spot for the remaining four days. The identity of these days will not be revealed to the blinded investigator who will later analyse the data. At the end of the thirty-day trial, the sensitivity and specificity of the device will be determined by assessing whether the data can be used to correctly identify the dates that participants induced nystagmus.
|Study Type :||Observational|
|Actual Enrollment :||18 participants|
|Official Title:||Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial|
|Actual Study Start Date :||August 23, 2018|
|Actual Primary Completion Date :||December 12, 2018|
|Actual Study Completion Date :||April 5, 2019|
All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
prototype device for monitoring dizziness
- Sensitivity and Specificity of a Computer Algorithm to Detect Artificially Induced Nystagmus [ Time Frame: 30 days ]Dates containing nystagmus. Of the ~450 days' worth of data captured during the study, 120 will contain artificially induced nystagmus. A computer algorithm has been developed at the University of East Anglia for detecting nystagmus. The key measurements are the sensitivity and specificity of the algorithm's results when applied to data captured during the trial. This measurement will be assessed post-trial.
- Post-trial Participant Questionnaire. [ Time Frame: 30 days ]A 2-page questionnaire producing qualitative and quantitative data. Participants rate different aspects of their experiences with the device using a sliding scale and have the opportunity to write more detailed descriptions.
- Compliance With the Device. [ Time Frame: 30 days ]1 - There is a minimum of 80% compliance with wearing the device for each single day of the trial for a minimum of 80% of participants. 2 There is a minimum of 80% compliance with wearing the device for the entirety of the 30-day trial for a minimum of 80% of participants.
- Data Usefulness [ Time Frame: 30 days ]The device provides less than 5% non-useful data for each participant. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured for each participant.
- Data Usefulness [ Time Frame: 30 days ]The device provides less than 5% non-useful data for the entirety of the 30-day trial across all participants. We will report the percentage of non-useful data (corrupted or flat-line data) that is captured over the entire trial, across all participants.
- Event Marker Functioning [ Time Frame: 30 days ]During a return visit, the event marker on each device will be pressed and the time noted. Post-trial, the data on the device will be examined to confirm that an event was recorded on the correct date. This will produce either a positive or negative outcome, depending on whether the event marker button press is present in the data or not. The percentage of identifiable button presses across all devices will be reported.
- Time Stamp Accuracy [ Time Frame: 30 days ]The difference will be calculated between the time noted by the research team and the time logged by the device when the event marker was activated. The time difference (in hh:mm:ss) will be calculated across all devices and we will report the average and standard deviation of the clock drift.
- Accelerometer Functioning [ Time Frame: 30 days ]Participants will perform a number of head movements and the device data will be examined visually to confirm that they can be identified. This will produce either a positive or negative outcome for each head movement, depending on whether the movement is visible in the data or not. The proportion of successfully identified head movements will be reported.
- Accuracy of Nystagmus Beat Direction [ Time Frame: 1 hour ]Participants will undergo caloric testing at the end of the trial, during which they will wear conventional Videonystagmography (VNG) goggles as well as the CAVA device. The beat direction (whether the fast phase of the nystagmus is towards the left or right ear) will be determined from both sources of data during the period of nystagmus captured. This will produce either a positive or negative outcome, depending on whether the beat direction matches in both data sources. The proportion of matches will be reported.
- Accuracy of Nystagmus Onset Time [ Time Frame: 1 hour ]Also from the data captured during caloric testing, the start time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
- Accuracy of Nystagmus Finishing Time [ Time Frame: 1 hour ]Also from the data captured during caloric testing, the finishing time of nystagmus will be identified from both the VNG data and data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
- Accuracy of Nystagmus Peak Time [ Time Frame: 1 hour ]Also from the data captured during caloric testing, the time at which the nystagmus reaches its maximum slow phase velocity will be calculated from the VNG data and the data captured by the CAVA device. The time difference (in mm:ss) will be calculated between the two data sources and the mean time difference will be reported.
- Accuracy of Nystagmus Frequency [ Time Frame: 1 hour ]Also from the data captured during caloric testing, the number of beats will be counted during the period identified as the nystagmus peak time. This will be calculated for both the VNG data and the data captured by the CAVA device. From the number of beats and time duration examined, the frequency of the nystagmus will be determined. The difference between the two systems will be calculated and the mean difference will be reported. The Unit of Measure will be Hz (number of beats per second).
- Data Drop-outs [ Time Frame: 30 days ]The device provides less 5 drop-outs for each single day of the trial for each participant. We will report the maximum number of drop-outs (periods when the device stopped logging) per participant, per day.
- Data Drop-outs [ Time Frame: 30 days ]The device provides less 60 drop-outs for the entirety of the 30-day trial across all participants. We will report the total number of drop-outs that occurred over the entire trial, across all participants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03661762
|Norfolk and Norwich University Hospitals NHS Foundation Trust|
|Norwich, Norfolk, United Kingdom, NR4 7UY|
|Principal Investigator:||John Phillips, Consultant||Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)|